JPMorgan analyst James Gordon lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma price target lowered to DKK 825 from DKK 850 at Berenberg
- Zealand Pharma’s Earnings Call: Strong Growth Amid Challenges
- Zealand Pharma Reports Strong 2025 Performance
- Zealand Pharma A/S (ZLDPF) Q3 Earnings Cheat Sheet
- Zealand Pharma’s Phase 3 Trial of Glepaglutide: A Potential Breakthrough for SBS Treatment